Seneste opdatering :
19/11/2024
Antibiotisk   Penicillin G sodium  
Injektion
Stabilitet i (vandige) opløsninger Stabilitet i blandinger Faktorer der påvirker stabiliteten Kompatibilitet Administrationsvej Bibliografi pdf
   Kemisk struktur  

Handelsnavn   Handelsnavn     

Handel navne er vejledende og hjælpestoffer sammensætning kan være forskellig afhængigt af landet og laboratorier

Benapen Brasilien
Bencilpenicilina Chile, Ecuador, Marokko
Benpen Australien, New Zealand
Bensylpenicillin Sverige
Benzapen Iran
Benzatec Sydafrika
Benzatron Brasilien
Benzylpenicillin Danmark, Finland, Norge, Sverige, Ægypten
Benzylpenicilline Tunesien
Biconcillina Ecuador
Crystapen Canada, Irland, Storbritanien
Declin Mexico
Fortepen Saudi-Arabien
Geepenil Finland
Natrium penicillin G Holland
Novopen Sydafrika
Pebencil Venezuela
Penbendox Mexico
Penibiot Spanien
Penicillin Norge
Penicillina G sodica Argentina, Chile, Colombia, Ecuador, Portugal
Penilevel Spanien
Sodiopen Spanien
Unicillina Spanien
Bibliografi   Injektion   Bibliografi : Penicillin G sodium  
Type offentliggørelse
13 Journal Stiles ML, Allen LV.
Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs.
Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
440 Journal Stiles ML, Tu YH, Allen LV.
Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs.
Am J Hosp Pharm 1989 ; 46: 1408-1412.
1057 Journal Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Journal Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1241 Journal Rayani S, Jamali F.
The stability of penicillin G sodium in 5% dextrose in water minibags after freezing.
Can J Hosp Pharm 1985 ; 38: 162-163.
1263 Journal Allwood MC, Brown PW.
The effect of buffering on the stability of reconstituted benzylpenicillin injection.
Int J Pharm Pract 1992 ; 1: 242-244.
1725 Journal Oliver C, Law S.
Compatibility of oxytocin, zidovudine, and penicillin G.
Can J Hosp Pharm 2001 ; 54: 112-113.
2056 Journal Vella-Brincat JWA, Begg EJ, Gallagher K, kirkpatrick CMJ, Zhang M, Frampton C, Chambers ST.
Stability of benzylpenicillin during continuous home intravenous therapy.
J Antimicrob Chemother 2004 ; 53: 675-677.
2087 Journal Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Journal Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
3012 Journal Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3227 Journal Simon B, Hancu G, Gy?resi A.
Application of capillary electrophoresis to the simultaneous determination and stability study of four extensively used penicillin derivatives
Braz J Pharm Sci 2014 ; 50, 3 : 521-527.
3520 Laboratorium Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3529 Laboratorium Ciprofloxacin – Summary of Product Characteristics
Hospira 2013
3540 Laboratorium Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3549 Laboratorium Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3580 Laboratorium Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3585 Laboratorium Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008
3643 Laboratorium Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3648 Journal Hossain M.A, Friciu M, Aubin S, Leclair G.
Stability of penicillin G sodium diluted with 0.9% sodium chloride injection or 5% dextrose injection and stored in polyvinyl chloride bag containers and elastomeric pump containers.
Am J Health-Syst Pharm 2014 ; 71:669-673.
3674 Laboratorium Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3702 Journal McDougall D.A.J, McWhinney.
Stability of buffered benzylpenicillin solutions for outpatient parenteral antimicrobial therapy.
J Pharm Pract and Res 2014 ; 44, 1: 26-28.
3931 Laboratorium Trimébutine (Débridat®) - Résumé des caractéristiques du produit
Pfizer Laboratoire 2016
3964 Journal Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4154 Laboratorium Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4319 Journal Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 Journal Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4590 Journal Smith E.K, McWhinney MPhil B.C.
Stability of buffered benzylpenicillin and flucloxacillin for a paediatric outpatient parenteral antibiotic therapy service.
J Pediatr Pharmacol Ther 2021 ; 51: 231-237.
4603 Journal Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4831 Journal Nezvalova-Henriksen K, Huseby Holm T, Nilsson N, Kjønniksen I, Tho I.
Frequently acquired drugs in neonatal intensive care and their physical compatibility.
Acta Paediatr 2022 ;111:2307–2314. 
4837 Journal De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales